Safety and efficacy of sitagliptin plus granulocyte-colony stimulating factor [lenograstim] in patients suffering from acute myocardial infarction
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Lenograstim (Primary) ; Sitagliptin (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms SITAGRAMI
- 10 Jun 2017 Biomarkers information updated
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 25 Jun 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.